BioLargo, Inc. · OTC:BLGO
BioLargo — Shareholder Meeting (September 2018)
22 slides from BioLargo's shareholder meeting presentation, Sep 26, 2018
Slide 1: Special Meeting of the Stockholders
We Make Life Better b BioLargo Special Meeting of the Stockholders September 26, 2018 Stock Symbol: BLGO Westminster, CA Safe Harbor Statement The ststements contsined herein, which are not historical, are fonrarJooking letements that are subject(o risks and uncertainties that could cause actual res
Slide 2: Sustainable Clean Technologies and Products
b ese: We Make Life Better Sustainable Clean Technologies and Products
Slide 3: BioLargo develops and commercializes sustainable patented products
BioLargo develops and commercializes sustainable patented products 18 Patents Commercial 5 Pendi ‘ending dL AOS Diverse markets Cuptipye Aon ‘Co ciean ree epee In-house eee Developing engineering GpBioLargo
Slide 4: Clean technologies based on all-natural iodine cycle
Clean technologies based on all-natural iodine cycle All-Natural lodine Cycle
Slide 5: Target addressable markets
Target addressable markets \, $1.48 ana: $228N8 Composting: $116M Transfer stations. $365M WWT Plants: $720M $2.34B Dental $264M Wound care: 75M Othopgaie $28" >$100M Eary regional market $4.5M Internal + external services $8.958 Beach head market: $344,
Slide 6: CupriDyne Clean Industrial Odor and VOC Eliminator
CupriDyne® Clean Industrial Odor and VOC Eliminator Eliminates odors — no masking Saves customers 25-50% per month Being Adopted by 5 of top 7 industry members- (complete Solution Engineering + Service and Maintenance) + Non-toxic + Non-sensitizing + Non-pesticide eva Ae ea
Slide 7: CupriDyne Clean in action
CupriDyne Clean in action
Slide 8: CupriDyne Clean in the $1B+ U.S. Market
CupriDyne Clean in the $1B+ U.S. Market U.S. Transfer Stations TAM: U.S. Wastewater Treatment TAM: Landfills TAM: $228 Composting: TAM $364 million/year $720 million/year million/year $118 million/year
Slide 9: Advanced Oxidation System (AOS)
Advanced Oxidation System (AOS) Clean Water Technology Low cost Lowest power consumption Flexible and modular Global water $675B treatment [ market py2028
Slide 10: Clyra Medical Technologies
Clyra Medical Technologies Gold standard advanced wound care Gentle & Effective + No cytotoxicity + Non sensitizing + No known acquired bacterial \ resistance FDA510(k) Liquid wound ‘ceansers woven and non application in process f
Slide 11: BioLargo Engineering
BioLargo Engineering Senior engineers — 35+ years experience with leading global firms External and internal services Subsidiary one year old; new © . customer relationships ©) BioLargo capable of carrying company Engineering, Science & Technologies to positive cash-flow
Slide 12: Experienced management with diverse talents
Experienced management with diverse talents Average 20+ years executive experience Industry experts Exceptionally qualified PhDs and engineers on staff Dennis Calvert, President and
Slide 13: BioLargo is a good partner
BioLargo is a good partner (3) university oF ALBERTA exe en UCLA SAS aTOM EWAN eyes | oiastcery | Sistemas ri) Environmental Research & Education Foundation NIC IRAP Alberta NSERC Wis « Qs EPCeR =< @ Futures: SUSTAIN 7) eg oR) DUBE HighTech innovation Awe 207 WINNER
Slide 14: We Make Life Better
We Make Life Better (" BioLargo Family tee BioLargo, nc. is a sustainable science, technology & full-service ironmental engineering company that makes life better by Symbol: Seiverng worts-ass products on sever eros abroad B LG O range of industries, with a drive to deliver clean water, clean air an
Slide 15: The Challenge
The Challenge 1. Company is under-financed and needs to rapidly execute on __ current expansion opportunities 2. We have a ‘tiger by the tail’ 3. OTC has become increasingly unfriendly
Slide 16: Time to move off OTC markets
Time to move off OTC markets * Most are prohibited from investing + Regulatory processes make it unprofitable for brokers to handle the paperwork * Trading often volatile + BioLargo outgrown OTC — time to break out
Slide 17: Solution: move to Nasdaq
Solution: move to Nasdaq « Nasdaq or equivalent * Capital we need to accelerate success + ~$7.5M cash to achieve $5M net shareholder equity * Syndicated & Underwritten placement >
Slide 18: Benefit from an exchange listing
BENEFIT FROM AN EXCHANGE LISTING ‘OTC UPGRADES TO NASDAQ ‘AVERAGE DAILY VOLUME (ADV) ANALYSIS listing removes investment restrictions for investors: 7 + Some institutional investors have by-laws that prevent investment in OTC stocks + Retail investors may be required to sign a waiver stating that th
Slide 19: What's missing
What's missing + Nasdaq minimum bid price + Most agree: A properly financed company with a clear pathway to grow revenues and ultimately make money is a good thing.
Slide 20: Reverse Split
Reverse Split + If you own 1% before the split, you will own 1% post split on a pre- money basis + No one is being asked to give up anything + What it is, and what it is not + Whatis unique about BioLargo? vy TIGER BY THE TAIL AND 2 MORE COMING
Slide 21: What is BioLargo Worth?
What is BioLargo Worth? + Does our market cap make rational sense? + Is the future bright? + Is having 3 disruptive platform technologies better than just one? + Are the technical claims true? + Does management have skin in the game? + Will capital make a difference? + Is the pathway to success clea
Slide 22: Is it worth the cost?
Is it worth the cost? + BioLargo will become known as a great American success story * honoring its Canadian innovators + staying true to its mission to support a greater good + Join us as we journey to “make life better”